GENE ONLINE|News &
Opinion
Blog

2022-09-28| SpecialTrials & Approvals

Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial

by Reed Slater
Share To
In a flurry of highs and lows for Biogen this week, the company voluntarily paid a $900 million settlement in a lawsuit brought about by a former employee regarding alleged paid kickbacks for physicians willing to prescribe the company’s multiple sclerosis drugs. At the other end of Biogen’s week, the company reported positive Phase 3 confirmatory trial results from its newest Alzheimer’s drug developed with Eisai, lecanemab, which is set for a regulatory decision in January next year. 

It's free! Log in now to read

LOG IN SUBSCRIBE NOW
LATEST
The Gene & Cell Therapy Landscape: Recent Approvals and Upcoming Therapeutics of Interest
2024-05-06
Exploring Key Areas of RNA Therapeutics Development: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Mastering Gene & Cell Therapy: Your Blueprint for Maximizing ASGCT Content
2024-05-06
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top